Hydros-TA: Phase II data

In the double-blind, international Phase II COR1.0 trial in 98 patients with osteoarthritis of the knee, Carbylan said a single intra-articular injection of Hydros or Hydros-TA had "positive results" in pain and function scores and showed the "potential to provide superior pain relief and improved function" vs. a single intra-articular injection of Synvisc-One. Hydros-TA was associated with a lower rate of treatment-related adverse events. Carbylan said the trial was not powered for efficacy and declined to provide additional details. ...